We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Clear Labs

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and a... read more Featured Products: More products

Download Mobile App





Groundbreaking Solution Enables Enhanced Screening and Genomic Surveillance of SARS-CoV-2 and its Mutations

By LabMedica International staff writers
Posted on 17 Sep 2021
Print article
Image: Clear Dx platform (Photo courtesy of Clear Labs)
Image: Clear Dx platform (Photo courtesy of Clear Labs)
The first-ever turn-key solution for whole genome sequencing (WGS) of COVID-19 is expected to help hospitals, reference labs, public health organizations and epidemiologists more easily identify and trace all strains of SARS-CoV-2.

Clear Labs (San Carlos, CA, USA), provider of the only fully-automated next-generation sequencing (NGS) platform for turnkey diagnostics, has launched Clear Dx WGS, the first automated WGS solution that determines the complete RNA sequence of the SARS-CoV-2 genome in less than 24-hours, a fraction of time, compared with traditional manual WGS workflows, requiring only minutes of hands-on time. The Clear Dx platform is powered by NGS, robotics and cloud-based analytics. As a result, Clear Dx WGS can more easily determine the nature of virus transmission by differentiating virus strains (including flagging super-spreader events), and monitoring mutations, which can lead to variants.

By delivering rapid sequencing of the whole genome, the Clear Dx platform provides fully-automated library preparation and management, including cDNA synthesis, amplification of targets, indexing, and nucleic acid clean-up. It also provides simplified WGS workflow with ~30 minutes hands-on time (i.e. 1-2 human touch points vs. several dozen touch points with existing manual WGS workflows). Additionally, the platform offers faster results - from days to less than 24 hours; improved consistency in sample processing and accuracy of results; and lower labor costs and greater lab productivity.

“This is a pivotal time for our understanding and management of the ongoing COVID-19 pandemic, and better, more accurate intel is critical,” said Jeff Field, Chief Commercial Officer at Clear Labs. “Our platform can identify different subtypes of the SARS-CoV-2 virus based on its genomic fingerprint. We recognize that it’s no longer enough to confirm cases, it’s about understanding the mutations and evolution of the virus, so the virus can be traced and understood. Ultimately, this leads to timely decisions which can be made to keep people safe. With our unique approach that democratizes genomics applications, Clear Dx WGS can quickly identify new subtypes, mutations, and variants to gain real-time clarity into virus transmission, so it's actionable.”

“In addition to WGS, the platform also features the Clear Dx SARS-CoV-2 Diagnostic Assay (EUA approved) which allows labs to perform diagnostic screening and genomic surveillance simultaneously,” added Field. “For the same price of a traditional PCR screening test, our fully-automated targeted NGS assay delivers same-day results and a comprehensive look into the virus - by differentiating positives into genomic subtypes and flagging clinically-relevant lineages or mutations, such as B.1.1.7, B.1.351, L452R, and D614G. Given the evolution of SARS-CoV-2, it's imperative that the market starts to adopt and implement NGS-based testing solutions to ensure that new strains such as B.1.1.7 are not being missed by conventional testing methods.”



Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Cardiovascular Disease POC Analyzer
cobas h 232 POC System
New
Real Time PCR Platform
VIASURE V-Lab96
New
SARS-CoV-2 Antigen Immunofluorescence System
Watmind SARS-CoV-2 Antigen Immunofluorescence System

Print article

Channels

Molecular Diagnostics

view channel
Image: A cancer cell during cell division (Photo courtesy of [U.S.] National Institutes of Health)

New Method Promises Rapid Isolation of Biomarker-Rich Extracellular Vesicles

A new method for isolating and analyzing cancer biomarkers from extracellular vesicles present in biological fluids is based on a novel magnetic particle based liquid biopsy chip. Extracellular vesicles... Read more

Microbiology

view channel
Image: Colored Transmission electron micrograph of Clostridium difficile bacterium forming an endospore (lower right, red oval). Clostridium difficile produce a toxin that irritates the colon and causes diarrhea (Photo courtesy of Kari Lounatmaa, PhD)

Quantity of Toxin in Stool Correlates with C. difficile Severity

Clostridioides difficile (syn. Clostridium difficile), also known as C. difficile, or C. diff are Gram-positive species of spore-forming bacteria. Clostridioides spp. are anaerobic, motile bacteria, ubiquitous... Read more

Technology

view channel
Image: Non-Invasive Nasal Swab Test Leverages Advanced Genomic Technology to Detect Lung Cancer Risk (Photo courtesy of Veracyte, Inc.)

Non-Invasive Nasal Swab Test Leverages Advanced Genomic Technology to Detect Lung Cancer Risk

A novel, non-invasive nasal swab test could support more timely and accurate lung nodule diagnosis. Veracyte, Inc. (South San Francisco, CA, USA) has announced that new expanded clinical validation data... Read more

Industry

view channel
Image: VSE Cat. No. 84800 with optional mobile table and phenolic work surface (Photo courtesy of HEMCO Corporation)

Hemco Offers VSE Balance Enclosure for Critical Procedures Involving Powders and Liquids

HEMCO Corporation (Independence, MO, USA) is offering its Vented Safety Enclosure (VSE) in 24-, 36- and 48-inch widths to accommodate an analytical balance and other small-scale lab processes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.